October 09, 2015 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Biomed Realty Trust Inc (NYSE:BMR), was announced concerning whether the takeover of Biomed Realty Trust Inc. by affiliates of Blackstone Real Estate Partners VIII for $23.75 per share is unfair to Biomed Realty Trust Inc stockholders.

The investigation by a law firm concerns whether certain officers and directors of Biomed Realty Trust Inc breached their fiduciary duties owed to NYSE:BMR investors in connection with the proposed acquisition.

On October 8, 2015, Biomed Realty Trust Inc (NYSE:BMR) announced that it has entered into an agreement with affiliates of Blackstone Real Estate Partners VIII, under which Blackstone will acquire all outstanding shares of common stock of Biomed Realty Trust Inc (NYSE:BMR) for $23.75 per share in an all-cash transaction valued at $8 billion.

However, given that at least one analyst has set the high target price for NYSE:BMR shares at $26.00 per share, the investigation concerns whether the offer is unfair to NYSE:BMR stockholders. More specifically, the investigation concerns whether the Biomed Realty Trust Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Biomed Realty Trust Inc reported that its annual Total Revenue rose from $637.31 million in 2013 to $674.61 million in 2014 and that its respective Net Income increased from $46.64 million to $193.78 million. Shares of Biomed Realty Trust Inc (NYSE:BMR) reached as high as $24.68 per share in January 2015.